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Summary We report a case with pulmonary veno-occlusive disease (PVOD) associated with
systemic sclerosis which exhibits strong resistance to pulmonary vasodilator.
A 55-year-old female with severe pulmonary hypertension was admitted to our hospital
to be introduced to epoprostenol infusion therapy. She was diagnosed as having pulmonary
arterial hypertension (PAH) associated with systemic sclerosis at the age of 51. Several aggres-
sive treatments with pulmonary vasodilators, including oral prostaglandin, endothelin receptor
antagonists, and phosphodiesterase 5 inhibitors, failed to improve her symptoms. We introduced
continuous intravenous epoprostenol therapy from 2g/kg/min for her. However, pulmonary
edema appeared and worsened in a dose-dependent manner. We made a diagnosis of PVOD
clinically at that time. Thereafter, pulmonary edema gradually disappeared consistent with the
reduction of the dose of epoprostenol infusion. She died of renal failure and infection 4months
after the introduction of epoprostenol infusion therapy. A histological examination revealed
severe stenosis and occlusions of pulmonary veins as well as pulmonary arteries over a wide
area. We suggest that prevalence of veno-occlusive type of disease could be one of the major
mechanisms of less responsive o
with PAH associated with conne
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Introduction
Recent advances regarding the treatment for pulmonary
hypertension, especially, for pulmonary arterial hyperten-
sion (PAH) have improved the prognosis of patients with
PAH [1,2]. Several reports have described that connec-
tive tissue diseases such as systemic sclerosis and systemic
lupus erythematosus could be complicated by severe PAH
which worsens their prognosis [3,4]. Pulmonary hyperten-
sion associated with connective tissue disease has been
categorized into PAH. Pulmonary veno-occlusive disease
(PVOD) has been described as a relatively rare cause of
pulmonary hypertension that affects predominantly post-
capillary pulmonary vessels. A major concern with PVOD is
the poor responsiveness to available pulmonary vasodilators,
especially, the risk of pulmonary edema with continu-
ous intravenous epoprostenol therapy [5,6]. We recently
experienced a case with PVOD associated with systemic
sclerosis which exhibited strong resistance to pulmonary
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Figure 1 Imaging of the case. Electrocardiogram at admission revea
precordial leads with right ventricular strain pattern (A). Chest X-ray
arch and pulmonary artery trunk (B). Echocardiography revealed dil
with ﬂattening of ventricular septum (C). High-resolution computed
opacities and septal thickness (D, arrow).in systemic sclerosis e45
asodilators, including continuous intravenous epoprostenol
herapy.
ase report
55-year-old female was admitted to our hospital for the
ntroduction of epoprostenol infusion therapy. She was diag-
osed as having systemic sclerosis at the age of 39 years.
he initial diagnosis of her pulmonary hypertension was
ade when she was 51 years old. She had been treated
ith beraprost since then. Thereafter, her symptoms of
yspnea gradually worsened associated with the increase
f pulmonary artery pressure in spite of the introduc-
ion of sildenaﬁl, ambrisentan, and home oxygen therapy
uring four years of the clinical course. Physical exami-
ation at admission revealed a heart rate of 80 bpm, a
lood pressure of 90/52mmHg, and a respiratory rate of
0 breaths/min. She had some signs of ﬂuid overload such
s jugular vein distension and lower extremity edema and
led right ventricular hypertrophy ﬁndings of tall R waves in right
demonstrated bilateral hilar enlargement, a prominent medial
atation of right ventricle, and normal left ventricular function
tomography of her chest revealed centrilobular ground-glass
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as in functional New York Heart Association class III.
rterial blood gas analysis revealed hypoxemia (pH 7.41,
aCO2 35mmHg, PaO2 79mmHg under O2 2 L/min). The
lectrocardiogram revealed a sinus rhythm of 80 bpm, and
ight ventricular hypertrophy ﬁndings of tall R waves in
ight precordial leads with right ventricular strain pattern
Fig. 1A). Chest X-ray (Fig. 1B) demonstrated bilateral hilar
nlargement, a prominent medial arch and pulmonary artery
runk. Echocardiography conﬁrmed dilatation of both the
ight atrium and right ventricle, and normal left ventric-
lar function (left ventricular ejection fraction of 62%)
ith ﬂattening of ventricular septum (Fig. 1C). Trans-mitral
ow velocity pattern revealed abnormal relaxation, and
he ratio of mitral inﬂow and mitral annular tissue Doppler
maging velocities (E/e′) was within the normal range
8.3). Right heart catheterization demonstrated severe pul-
onary hypertension (pulmonary arterial systolic pressure
o
a
p
igure 2 Histopathological ﬁndings. Macroscopic ﬁnding of heart; T
eft and right ventricles (A). Small pulmonary artery revealed prono
ypertension (B, Elastica van Gieson stain, ×200). Small pulmonar
hickening characteristics of pulmonary veno-occlusive disease (C, E
rea showed dilatation like angioma (D, hematoxylin and eosin stain
bserved (E, arrow). Intra-alveolar macrophages were observed (F, a
xistence of iron in the alveoli (G, arrow, Fe-stain, ×200). LV, left vH. Tada et al.
4mmHg, pulmonary arterial diastolic pressure 27mmHg,
ean pulmonary arterial pressure 48mmHg) in contrast to
he normal range of pulmonary capillary wedge pressure
4mmHg. Other important parameters were cardiac output
.9 L/min, (thermo dilution method) and pulmonary vascu-
ar resistance 540 dynes s cm−5. After these examinations,
poprostenol infusion therapy was introduced from the dose
f 2g/kg/min. However, pulmonary edema appeared and
er oxygenation worsened in a dose-dependent manner.
ased on this clinical course, we made a diagnosis of PVOD
linically and the dose of epoprostenol was 12g/kg/min.
hereafter, pulmonary edema gradually recovered con-
istent with the reduction of the dose of epoprostenol
nfusion. A high-resolution computed tomography (HRCT)
f her chest revealed centrilobular ground-glass opacities
nd septal thickness (Fig. 1D). Lung transplantation was
roposed as the sole treatment option to prolong her life,
ransverse section of the heart showing hypertrophy of both the
unced intimal ﬁbrosis, as typically seen in pulmonary arterial
y vein showed ﬁbrotic occlusive lesions with marked intimal
lastica van Gieson stain, ×200). The capillaries in the alveolar
, ×200). Macroscopic ﬁndings of lung; alveolar hemorrhage was
rrow, hematoxylin and eosin stain, ×40). Fe-stain revealed the
entricle; RV, right ventricle.
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but she declined. The patient died of renal failure and
infection 4months after the introduction of epoprostenol
infusion therapy. Histopathological examination of her heart
revealed hypertrophy of both ventricles without any appar-
ent pathological interstitial ﬁbrotic change (Fig. 2A). In
addition to the ﬁndings of small pulmonary arteries that
revealed pronounced intimal ﬁbrosis as typically seen in PAH
(Fig. 2B), small pulmonary vein also showed ﬁbrotic occlu-
sive lesions with marked intimal thickening characteristics
of PVOD (Fig. 2C). The capillaries in the alveolar area showed
dilatation like angioma (Fig. 2D) as well as the ﬁndings of
intra-alveolar hemorrhage (Fig. 2E—G). On the basis of these
pathological ﬁndings and clinical features, the patient was
diagnosed as having PVOD.
Discussion
Even though PAH and PVOD share many similarities, the
clinical classiﬁcation was modiﬁed to separate PVOD from
other forms of PAH following the Fourth World Symposium
on PAH held in 2008 at Dana Point, CA, USA [7]. It is cur-
rently well established that PAH associated with connective
tissue disease such as systemic sclerosis is frequently less
responsive or even refractory to pulmonary vasodilator ther-
apies. The likely mechanism is a selective dilatation of the
small pulmonary arteries without associated pulmonary ven-
odilatation which could cause an increase in trans-capillary
hydrostatic pressure. Several papers have described the use-
fulness of HRCT to predict the presence of PVOD [8,9]. Our
case also showed centrilobular ground-glass opacities and
septal thickness; however, the ﬁndings of HRCT suggesting
the presence of PVOD were obtained after the introduc-
tion of epoprostenol infusion therapy. Thus, we could not
suspect PVOD until then. Several studies suggested that
the frequencies of veno-occlusive types of disease in the
patients with PAH associated with connective tissue disease
might be larger than expected, and there is some evidence
from histopathological reports to support this hypothesis
[5]. However, the current deﬁnite diagnosis of PVOD can be
made histopathologically, thus, limiting the estimation for
the accurate involvements of this type of disease.
In conclusion, we report a case with PVOD associated
with systemic sclerosis which exhibits strong resistance
to pulmonary vasodilator. We suggest that prevalence
of veno-occlusive type of disease could be one of the
major mechanisms of less responsive or even refractory
[in systemic sclerosis e47
o pulmonary vasodilator therapies to patients with pul-
onary hypertension associated with connective tissue
isease.
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